← Evidence map

ArticleJournal of thoracic disease2026

Treatment-free survival with first-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: a critical analysis beyond PD-L1 expression.

Zouina Sarfraz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Treatment-free survival with first-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: a critical analysis beyond PD-L1 expression. | OpenQuestion